Enpatoran
As of the edition of 20 October 2026, Enpatoran is a small molecule: in active development; acts on TLR7 and TLR8.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2028
- Kind
- Small molecule
- Registered trials
- 12, 1 stopped early
- Disease areas
- Skin and connective tissue; Immune system; Bones, joints and muscles; Infections; Lungs and airways; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 2 | 4 | 2 | 1 | 1 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2018 to now |
| Merck Healthcare KGaA | Lead sponsor of trials | 2020 to now |